



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

27 January 2022  
EMA/CHMP/18383/2022  
Committee for Medicinal Products for Human Use (CHMP)

## **Summary of opinion<sup>1</sup> (initial authorisation)**

---

### **Paxlovid**

PF-07321332 / ritonavir

On 27 January 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Paxlovid, intended for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

The applicant for this medicinal product is Pfizer Europe MA EEIG.

Detailed recommendations for the use of this product are described in the product information (PI), which is published in English [here](#).

The European public assessment report (EPAR) will be published after the marketing authorisation has been granted by the European Commission and will make this information available in all official European Union languages.

---

<sup>1</sup> Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

